Doctor of Philosophy Program in Medical Sciences, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.
Center of Excellence for Medical Genomics, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.
Sci Rep. 2020 May 21;10(1):8472. doi: 10.1038/s41598-020-65577-x.
Platelet demand has increased around the world. However, the inadequacy of donors, the risk of transfusion-transmitted infections and associated reactions, and the refractory nature of platelet transfusions are among the limitations of allogeneic platelet transfusions. To alleviate these problems, we propose generating platelets in a laboratory that do not induce alloimmunity to human leukocyte antigen (HLA) class I, which is a major cause of immune reaction in platelet transfusion refractoriness. Induced pluripotent stem cells (iPSCs) were generated from peripheral blood mononuclear cells (PBMCs) of a healthy Thai woman. We then knocked out the β2-microglobulin (β2m) gene in the cells using paired CRISPR/Cas9 nickases and sequentially differentiated the cells into haematopoietic stem cells (HSCs), megakaryocytes (MKs) and platelets. Silencing of HLA class I expression was observed on the cell surface of β2m-knockout iPSCs, iPSC-derived HSCs, MKs and platelets. The HLA-universal iPSC-derived platelets were shown to be activated, and they aggregated after stimulation. In addition, our in vivo platelet survival experiments demonstrated that human platelets were detectable at 2 and 24 hours after injecting the β2m-KO MKs. In summary, we successfully generated functional iPSC-derived platelets in vitro without HLA class I expression by knocking out the β2m gene using paired CRISPR/Cas9 nickases.
血小板的需求在全球范围内有所增加。然而,供体不足、输血传播感染和相关反应的风险以及血小板输注的难治性等问题限制了同种异体血小板输注的应用。为了解决这些问题,我们提出在实验室中生成不会引起人类白细胞抗原(HLA)I 类同种免疫的血小板,这是血小板输注抵抗中免疫反应的主要原因。我们从一名健康泰国女性的外周血单核细胞(PBMC)中生成诱导多能干细胞(iPSC)。然后,我们使用成对的 CRISPR/Cas9 切口酶在细胞中敲除β2-微球蛋白(β2m)基因,并依次将细胞分化为造血干细胞(HSCs)、巨核细胞(MKs)和血小板。我们观察到β2m 敲除 iPSC、iPSC 来源的 HSCs、MK 和血小板的细胞表面 HLA I 类表达沉默。敲除 HLA 通用的 iPSC 来源的血小板被证明具有激活作用,并在刺激后聚集。此外,我们的体内血小板存活实验表明,在注射β2m-KO MK 后 2 和 24 小时可检测到人类血小板。总之,我们成功地使用成对的 CRISPR/Cas9 切口酶敲除β2m 基因,在体外生成了无 HLA I 类表达的功能性 iPSC 来源的血小板。